E156 Micro-Paper · Africa Clinical Trials

HIV Trial Saturation Index

HIV research dominates Africa's trial portfolio, yet even within HIV, trials con...

Africa Trials
615
US Trials
4,366
Gap Ratio
7x
Nations
54
Africa hosted 615 HIV trials versus 4,366 in the United States, a 7-fold disparity in research investment.
HIV Trial Saturation Index Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.711
HIV Trial Saturation Index by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
Regional Comparison Africa US Europe 0 2000 4000
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
No data
Research Profile Volume Growth Phase3 Complete Diversity
Enrollment Distribution Africa Reference 5000 10000 15000
Growth 2010-2026 Before After Africa 0 0 US 0 0 Europe 0 0
Why It Matters

HIV research dominates Africa's trial portfolio, yet even within HIV, trials concentrate in a handful of countries while high-prevalence nations in West and Central Africa remain underserved.

In the burden-versus-investment landscape of African health research, does the distribution of HIV trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Lorenz-curve area ratio as the primary estimand using registry metadata for each nation. Africa hosted 615 HIV trials (2.6% of its portfolio) compared to 4,366 in the United States, yielding a 0.0-fold disparity in per-population investment. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is limited by reliance on ClinicalTrials.gov alone, which may undercount locally registered African studies.
Question

In the burden-versus-investment landscape of African health research, does the distribution of HIV trials across African nations reveal a systematic research gap?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the Lorenz-curve area ratio as the primary estimand using registry metadata for each nation.

Robustness

Africa hosted 615 HIV trials (2.

Interpretation

6% of its portfolio) compared to 4,366 in the United States, yielding a 0.

Boundary

0-fold disparity in per-population investment.

Extra

Temporal analysis showed 17.

Extra

1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.

Extra

These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.

Extra

Interpretation is limited by reliance on ClinicalTrials.

Extra

gov alone, which may undercount locally registered African studies.